

Metformin Suppresses Expression of the Selenoprotein P gene via an AMPK-FoxO3a Pathway in
H4IIEC3 Hepatocytes

Hiroaki Takayama¹, Hirofumi Misu¹, Hisakazu Iwama², Keita Chikamoto^{1,3}, Yoshiro Saito⁴, Koji Mura⁵, Atsushi Teraguchi⁶, Fei Lan¹, Akihiro Kikuchi¹, Reina Saito¹, Natsumi Tajima¹, Takayoshi Shirasaki^{1,7}, Seiichi Matsugo^{8,9}, Ken-ichi Miyamoto^{10,11}, Shuichi Kaneko¹, and Toshinari Takamura¹

¹ Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

² Life Science Research Center, Kagawa University, Ikenobe 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

³ Division of Natural System, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, 920-1192, Japan

⁴ Systems Life Sciences, Department of Medical Life Systems, Faculty of Medical and Life Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan

⁵ Departments of Advanced Medicine, Kagawa University, Ikenobe 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

⁶ Department of Hospital Pharmacy, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

⁷ Department of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

⁸ Division of Material Engineering, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, 920-1192, Japan

⁹ Institute of Science and Engineering, Faculty of Natural System, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, 920-1192, Japan

¹⁰ Department of Hospital Pharmacy, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

¹¹ Department of Medicinal Informatics, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

Running title: *Metformin and FoxO3a-mediated Suppression of SeP Expression*

To whom correspondence should be addressed: Toshinari Takamura, Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa,

Ishikawa 920-8641, Japan, Tel.: +81-76-265-2233; Fax: +81-76-234-4250, E-mail: ttakamura@m-kanazawa.jp

Capsule

Background: The suppression of selenoprotein P production may be a novel therapeutic target for reducing insulin resistance.

Results: Selenoprotein P expression was suppressed by metformin treatment, but co-administration of AMPK inhibitor or FoxO3a siRNA cancelled this suppression.

Conclusion: Metformin suppresses selenoprotein P expression via AMPK/FoxO3a pathway.

Significance: AMPK/FoxO3a pathway in the liver may be a therapeutic target for type 2 diabetes.

SUMMARY

Selenoprotein P (SeP; encoded by *SEPP1* in humans) is a liver-derived secretory protein that induces insulin resistance in type 2 diabetes. Suppression of SeP might provide a novel therapeutic approach to treating type 2 diabetes, but few drugs that inhibit *SEPP1* expression in hepatocytes have been identified to date. The present findings demonstrate that metformin suppresses *SEPP1* expression by activating AMPK and subsequently inactivating FoxO3a in H4IIEC3 hepatocytes. Treatment with metformin reduced *SEPP1* promoter activity in a concentration- and time-dependent manner; this effect was cancelled by co-administration of an AMPK inhibitor. Metformin also suppressed *Sepp1* gene expression in the liver of mice. Computational analysis of transcription factor

binding sites conserved among the species resulted in identification of the FoxO-binding site in the metformin-response element of the *SEPP1* promoter. A luciferase reporter assay showed that metformin suppresses Forkhead-response element activity and a ChIP assay revealed that metformin decreases binding of FoxO3a, a direct target of AMPK, to the *SEPP1* promoter. Transfection with siRNAs for *Foxo3a*, but not for *Foxo1*, canceled metformin-induced luciferase activity suppression of metformin-response element of the *SEPP1* promoter. The overexpression of FoxO3a stimulated *SEPP1* promoter activity and rescued the suppressive effect of metformin. Metformin did not affect FoxO3a expression, but it increased its phosphorylation and decreased its nuclear localization. These data provide a novel mechanism of action for metformin involving improvement of systemic insulin sensitivity through the regulation of SeP production and suggest an additional approach to the development of anti-diabetic drugs.

INTRODUCTION

Selenoprotein P (SeP; encoded by *SEPP1* in humans) is a secretory protein produced mainly by the liver (1, 2). SeP contains 10 selenocysteine residues and is known to transport the essential trace element selenium from the liver to the rest of the body (3, 4). Our laboratory reported recently that SeP functions as a hepatokine that contributes

to insulin resistance in type 2 diabetes (5). Using comprehensive gene expression analyses in humans, hepatic gene expression levels of *SEPP1* were found to be positively correlated with the severity of insulin resistance in patients with type 2 diabetes. Moreover, treatment with purified SeP protein impairs insulin signal transduction in both cell culture and animal models. Importantly, the RNA interference-mediated knockdown of SeP improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes, suggesting that the suppression of SeP production in the liver may be a novel therapeutic target for reducing insulin resistance in type 2 diabetes (5). However, few drugs that inhibit the production of SeP by hepatocytes have been identified to date.

Metformin is widely used as an anti-diabetic drug globally. The primary target of metformin action is the liver, which abundantly expresses organic cation transporter (Oct)-1, a transporter for metformin (6, 7). Adenosine monophosphate-activated protein kinase (AMPK) mediates primarily the glucose-lowering actions of metformin, including the suppression of hepatic gluconeogenesis (8). In contrast, several reports indicate that the oral administration of metformin in humans increases insulin sensitivity in skeletal muscle, increases serum adiponectin, and improves aortic arteriosclerosis (9–11). These reports suggest that orally administered metformin also exerts beneficial actions on tissues other than the liver, in which expression levels of Octs are lower. To date, however, the molecular mechanisms underlying the systemic actions of metformin are not fully understood.

Forkhead box protein O3a (FoxO3a), which belongs to Forkhead transcription factors of the FoxO subfamily (FoxOs), is reported to be involved in cell cycle arrest (12), apoptosis (13), and the oxidative stress response (14, 15). Recently, Greer *et al.* showed that FoxO3a, but not FoxO1, is directly phosphorylated and activated by AMPK *in vitro* (16). FoxO3a is reported to positively regulate mitochondria-related genes, such as uncoupling proteins (UCPs), in mouse embryonic fibroblasts, suggesting that the direct regulation of FoxO3a by AMPK plays a crucial role in the control of the cellular energy balance. The phosphorylation of FoxO3a by AMPK was also identified in C2C12 myotubes (17), aortic vascular endothelial cells (18), and A549 lung cancer cells (19). However, the role of the AMPK/FoxO3a pathway in hepatocytes, an important target of metformin, remains unknown.

We demonstrate here that metformin suppresses *SEPP1* gene expression by activating AMPK and subsequently inactivating FoxO3a in H4IIEC3 hepatocytes. These results suggest a novel mechanism underlying the glucose-lowering action of metformin.

EXPERIMENTAL PROCEDURES

Materials- The antibodies against AMPK α , phospho-AMPK α , FoxO1, FoxO3a, acetylated-Lys, and Lamin A/C were purchased from Cell Signaling Technology (Beverly, MA). Antibody against phospho-Ser/Thr/Tyr was purchased from AnaSpec (San Jose, CA). Antibody against GAPDH was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 5-aminoimidazole-4-carboxamide ribonucleotide

(AICAR), and 6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrazolo[1,5-a]-pyrimidine (Compound C) were purchased from Sigma-Aldrich (St. Louis, MO). FoxO3a expression vector was provided from Ajinomoto Pharma (Tokyo, Japan) described before (20). Selenious acid was purchased from WaKo Pure Chemical Industries, Ltd. (Osaka, Japan). Metformin was provided by Dainippon Sumitomo Pharma (Osaka, Japan), but this company had no role in the study design and has no financial interest in the results.

Generation of Plasmid Constructs- The human *SEPP1* promoter region has been described previously (21). Fragments of approximately 1800 bp from the human *SEPP1* promoter region and the deletion promoter region were amplified by PCR using normal human genomic DNA as a template and the primer pairs shown in Table 1. The PCR product was subcloned into the luciferase reporter gene plasmid pGL3-basic (Promega; Madison, WI) and termed “*SEPP1*-Promoter-Luc”, “Mut-A”, “Mut-B”, “Mut-C”, “Mut-D”, “Mut-E”, “Mut-Δ1”, “Mut-Δ2”, and “Mut-Δ3”. Putative FoxO binding site deficient vector were generate using QuickChange Lightning Site-Directed Mutagenesis Kits (Agilent Technologies; Santa Clara CA), according to the manufacturer’s instructions. All inserts were confirmed by DNA sequencing.

Cell Culture- Studies were performed using the rat hepatoma cell line H4IIEC3 (American Type Culture Collection; Manassas, VA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies Corporation, Carlsbad,

CA) and supplemented with 10% fetal bovine serum (Life Technologies), 2 mmol/l L-Glutamin (WaKo Pure Chemical Industries, Ltd.; Osaka, Japan), 100 units/ml penicillin, and 0.1 mg/ml streptomycin (WaKo). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.

Measurement of GPx activity- To measure cellular glutathione peroxidase (cGPx) activity, a coupled enzyme assay, which was performed by following the oxidation of NADPH, was used as described previously (22). In brief, cells were cultured with DMEM/10%FBS or DMEM/10%FBS +100 nM selenious acid or DMEM/10%FBS +1000 nM selenious acid at 72 h. Then cells were fractured with homogenate buffer containing 0.25 M Sucrose, 50 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 0.1 mM 2-Mercaptoethanol. The assay conditions were as follows: for the cGPx assay, 0.1 M phosphate buffer, pH 7.4, 0.2 mM NADPH, 0.5 mM EDTA, 1 mM NaN₃, 2 mM GSH, 1 unit/ml of GSH reductase, and 30 μM hydrogen peroxide. The oxidation of NADPH was followed at 340 nm at 37 °C, and unit of the enzyme activity was expressed as μmol of NADPH oxidized per minute.

Transfection and Luciferase Reporter Gene assay- H4IIEC3 cells were grown in 24-well plates and transfected with 0.4 μg of plasmid DNA per well together with 1.2-μL FuGENE6 (Promega). For the luciferase reporter gene assays, 0.4 μg of firefly luciferase promoter construct was co-transfected with 0.01-μg renilla luciferase control plasmid (pRL-SV40; Promega), and/or 0.05-0.4 μg of plasmids expressing FoxO3a, or empty control plasmids resulting in a total DNA amount of 0.41-

0.81 µg per well. 24 hours later, cells were treated with the indicated reagents, such as metformin, in DMEM/10% FBS for the indicated times. After 48 hours, luciferase activities were measured using the Dual Luciferase assay system (Promega), as described previously (20).

siRNA transfection in H4IIEC3 hepatocytes- H4IIEC3 hepatocytes were grown in 24-well plates and transiently transfected with 10 nM small interfering RNA (siRNA) duplex oligonucleotides using 1-µL Lipofectamine™ RNAiMAX (Life Technologies) by the reverse-transfection method according to the manufacturer's instructions. *Foxo1* and *Foxo3a*-specific siRNAs with the following sequences were synthesized (Thermo Scientific): *Foxo1* #A: 5'-GACAGCAAUAAGUUAUG-3' (sense), *Foxo1* #B: 5'-UUUGAUAACUGGAGUACAU-3' (sense), *Foxo3a* #A: 5'-GAACGUUGUUGGUUGAAC-3' (sense) and *Foxo3a* #B: 5'-CGUCAUGGGUCACGACAAG-3' (sense). Negative control siRNA was also utilized (Thermo Scientific). 24 hours after transfection, the cells were treated with metformin for 24 hours followed by the extraction of total RNA.

Adenovirus-mediated gene transfer in H4IIEC3 hepatocytes- Cells were transfected with adenoviruses as described previously (5). Briefly, H4IIEC3 hepatocytes were grown to 90% confluence in 24-well multi-plates and transfected with adenoviruses encoding dominant negative (DN) $\alpha 1$ and $\alpha 2$ AMPK, constitutive active (CA) AMPK, or LacZ for 4 hours. The cells were incubated with DMEM for 24 hours after removing

the adenoviruses; total RNA was then extracted.

Quantitative RT-PCR- Total RNA was extracted from cultured H4IIEC3 hepatocytes using a Genelute Mammalian Total RNA Miniprep Kit (Sigma). The reverse-transcription of 100 ng of total RNA was performed using a High-capacity cDNA Reverse Transcription Kit (Life Technologies), according to the manufacturer's instructions. Quantitative RT-PCR (qRT-PCR) was performed using TaqMan probes (ACTB: 4352340E; *Foxo1*: Rn01494868_m1; *Foxo3*: Rn01441087_m1; *G6pc*: Rn00565347_m1; *Pck1*: Rn01529014_m1; and *Sepp1*: Rn00569905_m1) and the 7900HT Fast Real-Time PCR System (Life Technologies), as described previously (23).

Western blotting- Treated cells were collected and lysed as described previously (20). Protein samples (10 µg per lane) were subjected to SDS-PAGE and transferred to PVDF membranes using the iBlot Gel Transfer system (Life Technologies). The membranes were blocked, incubated with primary antibody, washed, and incubated with the secondary HRP-labeled antibody. Bands were visualized with the ECL Prime Western Blotting Detection System (GE Healthcare UK Ltd; Amersham Place, Little Chalfont, UK) and LAS-3000 (Fujifilm; Tokyo, Japan). A densitometric analysis of blotted membranes was performed using ImageJ software.

Immunoprecipitation- Immunoprecipitation of serine/threonine/tyrosine phosphorylated proteins or lysine acetylated proteins were carried out using Dynabeads Protein G Immunoprecipitation Kit (Life Technologies), according to the manufacturer's instructions. The nuclear and

cytoplasmic fractions were extracted using a NEPER Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce; Rockford, IL).

Detection of the conserved transcription factor binding sites using multiple genome alignments-

The Ensembl 12-way Enredo-Pecan-Ortheus (EPO) eutherian multiple alignments (12-way EPO alignments) (24, 25) were downloaded from ftp.ensembl.org/pub/release-65/emf/ensembl-compara/epo_12_eutherian/. The 12-way EPO was excised to obtain the alignment block corresponding to the human genome coordinates from 10-kb upstream of the coding sequence of *SEPP1*, including the start codon. To predict the conserved transcription factor binding sites (TFBSs), the 10-kb upstream genome sequence for each of the 12 species was searched using TRANSFAC (26) MATCH™ program (27) (version 6.1) with varied thresholds. Then, the predicted TFBSs were mapped on the alignments and the conserved TFBSs for *SEPP1* were identified.

Chromatin immunoprecipitation assay- A chromatin immunoprecipitation (ChIP) assay was carried out using the ChIP IT Express Enzymatic Kit (Active Motif; Carlsbad, CA), according to the manufacturer's instructions. In brief, HepG2 cells were treated with metformin 6 hours before being fixed and homogenized. Following centrifugation, the supernatant was used for chromatin samples. Chromatin samples were incubated with protein G-coated magnetic beads and ChIP grade FoxO1 or FoxO3a antibodies (abcam; Cambridge, MA) overnight at 4°C. Following washing and elution, a reaction solution was used as the template for PCR. PCR primers were set for amplification of

the Mut-DΔ2 region of the *SEPP1* promoter, as follows:

Forward: 5'-GCACTTGCTACTTTCTTTTAAGTTG -3'; and

Reverse: 5'-CACAGCAGCACACTCTGATATTTAT -3'.

Animals- 12 weeks old C57BL/6J female mice were obtained from CLEA Japan, Inc. (Tokyo, Japan). All animals were housed in a 12 hours light/dark cycle and allowed free access to food and water. Following the fasting for 4 hours, mice were administered 300 mg/kg of metformin. 4 hours later, mice were anesthetized and sacrificed to allow isolation of liver tissue.

Statistical Analysis- Results are expressed as means ± standard deviation (SD). Significance was tested by one-way analysis of variance (ANOVA) with the Bonferroni method and differences were considered statistically significant at a *P* value of less than 0.05.

RESULTS

Metformin suppresses SEPP1 expression at the promoter level- The effects of metformin on *Sepp1* expression in H4IIEC3 hepatocytes were examined. Metformin suppressed *Sepp1* mRNA expression in a concentration- and time-dependent manner, similarly to *G6pc* and *Pck1* that encode representative gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 1, respectively (Fig. 1A and 1B). These results are consistent with a previous report using rat primary hepatocytes (28). Next, the effects of metformin on *SEPP1* promoter activity were examined. The human *SEPP1* promoter region was cloned to a luciferase reporter vector as reported previously (21). The present sequence

completely corresponded to the reference sequence of the the National Center for Biotechnology Information (NCBI), but it missed one thymidine against the sequence of previous report (accession number Y12262) (Supplement Fig. S1). Similar to the mRNA results, metformin suppressed *SEPP1* promoter activity in a concentration- and time-dependent manner (Fig. 1C & 1D), suggesting that it directly decreases *SEPP1* transcriptional activity in H4IIEC3 hepatocytes.

To confirm whether the present experimental condition (DMEM/10%FBS) supplied selenium sufficiently enough to synthesize selenoproteins for cultured cells, cGPx activity was measured with or without additional selenium supplement. Supplement Fig. S2 indicated that supplementation of 100 nM or 1000 nM selenious acid to DMEM/10%FBS increased cGPx activity more than 3 times, suggesting that our experimental condition was insufficient to maximize selenoprotein synthesis. However, the current activity of cGPx in the cells cultured at DMEM/10%FBS (233 U/g) corresponded to the levels previously reported in the normal rat liver tissue (120 - 1800 U/g) (29, 30). Because these results suggest that the culture condition of DMEM/10%FBS was physiological, we used this condition in the following cellular experiments.

The action of metformin on *Sepp1* was also examined in mice. Following the fasting for 4 hours, 12 weeks old female C57BL/6J mice were administrated 300 mg/kg of metformin. Metformin decreased blood glucose levels by 30% (Fig. 1E) and tended to down-regulate gene expression for *G6pc* and *Pck1* after 4 hours. Gene expression of

Sepp1 was significantly decreased by metformin (Fig. 1F). These results indicate that metformin suppresses gene expression for *Sepp1* in the liver of mice, as well as in the cultured hepatocytes.

Metformin suppresses SEPP1 promoter activity via AMPK activation- Metformin is known to exert anti-diabetic effects by activating AMPK pathways (31). Hence, to determine whether AMPK pathways are involved in the metformin-induced suppression of *SEPP1* promoter activity, cells were treated with compound C, a representative AMPK inhibitor. Findings confirmed that the metformin-induced phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) was canceled by the co-administration of compound C in H4IIEC3 hepatocytes (Fig. 2A). Co-administration of compound C partly rescued the cells from the inhibitory effects of metformin on the *SEPP1* promoter (Fig. 2B), and increased *SEPP1* promoter activity in the absence of metformin (Fig. 2B). In contrast, treatment with AICAR, a known activator of AMPK, decreased *SEPP1* promoter activity similarly to metformin (Fig. 2C). To determine whether AMPK pathways were involved in *SEPP1* promoter activity, H4IIEC3 hepatocytes were infected with an adenovirus encoding CA- or DN-AMPK. Transfection with CA-AMPK suppressed *Sepp1* and *G6pc* mRNA expression (Fig. 2D) while transfection with DN-AMPK enhanced *Sepp1* and *G6pc* mRNA expression (Fig. 2E). These results suggest that metformin decreases *SEPP1* promoter activity, at least partly, by activating AMPK.

Metformin-response element in the SEPP1

promoter includes the FoxO binding site- To determine the nature of the metformin-response element in the *SEPP1* promoter region, several deletion mutants of the *SEPP1* promoter were constructed (Fig. 3A). Promoter activity of Mut-A to Mut-D, but not Mut-E, was suppressed by metformin treatment (Fig. 3A) indicating that the metformin-response element of the *SEPP1* promoter exists in Mut-D. Additional deletion mutants of Mut-D were constructed and named Mut-D Δ 1 to D Δ 3. Mut-D Δ 1 and D Δ 2, but not Mut-D Δ 3, were suppressed by metformin (Fig. 3B), indicating that the metformin-response element in the *SEPP1* promoter is localized in the Mut-D Δ 2 sequence. Using computational analysis to identify conserved TFBSs among the species (see EXPERIMENTAL PROCEDURES), several putative TFBSs were identified in the Mut-D Δ 2 sequence (Supplement Fig. S3). Because early reports indicate that AMPK directly phosphorylates FoxO3a and regulates its transcriptional activity (16), this investigation focused on the two putative FoxO binding sites (Fig. 4A).

Metformin suppresses FoxO activity via AMPK activation- To determine whether metformin treatment influences FoxO activity, a forkhead-response element (FHRE)-Luc vector that includes three tandems of FHREs ligated with a luciferase gene was utilized (32). This vector was used as a reporter of FoxO-responsive promoter activity (33). Metformin treatment suppressed FHRE activity, and concurrent treatment with compound C completely cancelled this suppression (Fig. 4B). In addition, treatment with compound C stimulated

FHRE activity in the absence of metformin (Fig. 4B), while AICAR treatment suppressed FHRE activity (Fig. 4C). These results suggest that metformin suppresses FHRE activity via AMPK activation. To determine the critical FoxO binding site for metformin-induced *SEPP1* suppression, we constructed luciferase vectors which deleted either of two putative FoxO binding sites and named Mut-D Δ 2- Δ FoxO #A or #B, respectively (Supplement Fig. S4). Luciferase assay using these vectors revealed that putative FoxO binding site #B was essential for metformin-induced *SEPP1* suppression (Fig. 4D). Because the assays using these vectors are not specific to FoxO3a activity, the interaction of FoxO proteins with DNA sequences in the *SEPP1* promoter was examined using a ChIP assay. For the ChIP assay, HepG2 cells were utilized to evaluate the human *SEPP1* promoter. Metformin suppressed *SEPP1* expression in HepG2 cells as well as H4IIEC3 cells (data not shown). The ChIP assay indicates that treatment with metformin decreased the binding of FoxO3a to *SEPP1* promoter, whereas it increased the binding of FoxO1 (Fig. 4E). These results suggest that FoxO3a, but not FoxO1, is associated with the metformin-induced suppression of *SEPP1* expression.

Metformin suppresses SEPP1 expression via FoxO3a inactivation- Next, we examined whether the specific knockdown of endogenous *Foxo3a* or *Foxo1* affects *Sepp1* expression in H4IIEC3 hepatocytes. Transfection with *Foxo3a*- or *Foxo1*-specific siRNA resulted in a ~50% reduction in mRNA levels of *Foxo3a* or *Foxo1* (Fig. 5A). Knockdown of both *Foxo1* and *Foxo3a* resulted in

a significant down-regulation of *Sepp1* expression (Fig. 5A). Interestingly, mRNA levels of *G6pc* were decreased by *Foxo3a* knockdown (Fig. 5A), suggesting that not only FoxO1 but also FoxO3a positively regulates the expression of the gluconeogenesis-related genes in H4IIEC3 hepatocytes. Next, we assessed whether knockdown of *Foxo3a* selectively affects the inhibitory action of metformin on *SEPP1* promoter. Transfection with siRNAs for *Foxo3a*, but not for *Foxo1*, canceled metformin-induced suppression of Mut- $\Delta 2$ luciferase activity (Fig. 5B). These results suggest that the metformin-induced suppression of *Sepp1* is dependent on FoxO3a, but not on FoxO1.

Whether FoxO3a overexpression influences the action of metformin on *SEPP1* promoter activity was also investigated. The FoxO3a protein was overexpressed in a concentration-dependent manner in cells transfected with the pCMV6-FoxO3a expression vector (Fig. 5C). Overexpression of FoxO3a significantly enhanced *SEPP1* promoter activity (Fig. 5D), and transfection with pCMV6-FoxO3a rescued the cells from the suppressive effect of metformin on *SEPP1* promoter activity in a concentration-dependent manner (Fig. 5D and 5E). These results indicate that metformin decreases *SEPP1* promoter activity and gene expression via FoxO3a inactivation in H4IIEC3 hepatocytes.

Metformin decreases FoxO3a protein in the nuclear components- To elucidate the mechanism by which metformin inactivates FoxO3a, phosphorylation and acetylation of FoxO3a were examined in hepatocytes treated with metformin.

Metformin treatment neither altered mRNA levels of *Foxo3a* (Fig 6A) nor protein levels of FoxO3a (Fig. 6B). However, immunoprecipitation experiments revealed that treatment with metformin phosphorylated FoxO3a, but not FoxO1 in H4IIEC hepatocytes (Fig. 6B and 6C, Supplementary Fig. S5). Because a previous report indicated that FoxO3a, as well as FoxO1, is deacetylated by sirtuin family proteins downstream of AMPK (34), we examined the deacetylation of FoxO3a and FoxO1. Acetylation of both FoxO1 and FoxO3a was unaffected by metformin administration (Fig. 6B and 6C, Supplementary Fig. S5). To determine the intracellular localization of FoxO3a, the cytosolic and nuclear components of the FoxO3a protein were fractioned. FoxO3a and FoxO1 protein levels were decreased by metformin treatment in the nuclear fraction (Fig. 6D). These results suggest that metformin inactivates FoxO3a by decreasing FoxO3a protein levels in the nucleus and subsequently inhibiting the binding of FoxO3a to the *SEPP1* promoter.

DISCUSSION

Our data demonstrate that metformin suppresses production of the insulin resistance-inducing hepatokine SeP by activating AMPK and subsequently inactivating FoxO3a in H4IIEC3 hepatocytes. During the course of this study, it was reported that metformin decreases mRNA levels of *Sepp1* in rat primary hepatocytes (28), however, the molecular mechanisms by which metformin reduces the expression of *Sepp1* were not fully understood. Our data demonstrate that the

AMPK/FoxO3a pathway downstream of metformin action plays a major role in the regulation of *SEPP1* expression in cultured hepatocytes. Our data suggest a previously unrecognized mechanism of action of metformin in combating the systemic insulin resistance in type 2 diabetes.

The finding that FoxO3a positively regulates *Sepp1* and *G6pc* expression in H4IIEC3 hepatocytes supports the suggestion that FoxO3a plays an important role in glucose homeostasis. The ability of FoxO1 to increase the expression of gluconeogenic genes has been confirmed (35). To date, however, little information concerning the involvement of FoxO3a in glucose metabolism is available. Certainly, no defects in glucose metabolism have been described in FoxO3a deficient mice (36) suggesting that the function of FoxO3a in glucose metabolism is compensated for by FoxO1. Indeed, Haeusler *et al.* (37) reported that triple liver-specific ablation of FoxO1, FoxO3a, and FoxO4 causes a more pronounced hypoglycemia and increased insulin sensitivity in mice compared to a single knockout of FoxO1. The present findings indicate that FoxO proteins, including FoxO3a, regulate hepatic glucose metabolism in a coordinated manner. These data reveal that FoxO3a, the downstream target of metformin/AMPK, positively regulates *SEPP1* transcriptional activity in cultured hepatocytes independently of FoxO1 and suggest that FoxO3a participates in glucose homeostasis via regulation of the hepatic production of SeP, an insulin resistance-inducing hepatokine.

Knock down of *Foxo3a*, but not *Foxo1*, rescued

the cells from metformin-induced inactivation of *SEPP1* promoter although knockdown of both *Foxo3a* and *Foxo1* down-regulated *Sepp1* in the absence of metformin (Fig. 5A and 5B). These results are in harmony with early reports showing that FoxO1 positively regulates *Sepp1* expression in cultured hepatocytes (38, 39). The current data suggest that both FoxO3a and FoxO1 positively regulate expression of *SEPP1* in the basal conditions, but FoxO3a has a dominant role in the suppression of *SEPP1* downstream of metformin/AMPK pathway in H4IIEC3 hepatocytes. Interestingly, metformin selectively phosphorylated and deacetylated FoxO3a, but not FoxO1 (Fig. 6B and 6C). This FoxO3a-selective phosphorylation by metformin is consistent with the previous report showing that AMPK-induced phosphorylation displays a strong preference toward FoxO3 compared with FoxO1 by using *in vitro* kinase assays (16).

The current study is the first to demonstrate the decreased nuclear localization and subsequent transcriptional inactivation of FoxO3a by AMPK downstream of metformin in the cultured hepatocytes. Greer *et al.* (16) identified FoxO3a as a direct phosphorylation target of AMPK using *in vitro* kinase assays. However, the authors reported that phosphorylation by AMPK increases FoxO3a transcriptional activity without affecting FOXO3A subcellular localization in mouse embryonic fibroblasts or 293T cells. A similar activation of FoxO3a by AMPK was reported in C2C12 myotubes (17). In this respect, our results suggest that the AMPK-induced inactivation of FoxO3a is hepatocyte-specific. When FoxO proteins are

phosphorylated by Akt, the dissociation of nuclear co-factors from FoxO is thought to be required for nuclear exclusion of FoxO (40). Hence, the difference in nuclear co-activator/co-repressor recruitment between hepatocytes and other cells might explain differences in the action of AMPK on FoxO3a cellular localization and transcriptional activity. Notably, the siRNA-induced knockdown of *Foxo3a* decreased *Sepp1* and *G6pc* mRNA levels in H4IIEC3 hepatocytes, suggesting that the AMPK/FoxO3a pathway in the liver regulates gluconeogenesis and the production of the hepatokine SeP. These findings shed light on a previously unrecognized role for the AMPK/FoxO3a pathway in the regulation of glucose metabolism in the liver.

The cancellation of the metformin-induced suppression of SeP by compound C, a known inhibitor of the AMPK pathway, was only partial (Fig. 2B). Likewise, the overexpression of FoxO3a only partially canceled the suppressive action of metformin on *Sepp1* gene expression (Fig. 6D & 6E). These results suggest that metformin decreases *Sepp1* gene expression through both AMPK/FoxO3a-dependent and other independent pathways. Recently, Kalender *et al.* (41) reported that metformin acts to suppress mTORC1 signaling in an AMPK-independent manner. In addition, Guigas *et al.* (42) found that metformin inhibits glucose phosphorylation in primary cultured hepatocytes independently of AMPK activity. Additional studies are needed to elucidate the AMPK-independent actions of metformin on *Sepp1* expression in H4IIEC3 hepatocytes.

The present sequence of *SEPP1* promoter

completely corresponds to the refseq of the NCBI, but it misses one thymidine against the sequence of a previous report (21). This site had been reported as SNP site (reference SNP ID: rs201851607). Because both allele origin and minor allele frequency of this SNP site are not available, it is difficult to prove which genome sequence is “correct”. At least, this SNP site does not seem to affect basal *SEPP1* promoter activity. In addition, metformin responsible element identified in the current paper locates in the other region of the SNP site. Thus, we consider that the effect of this SNP on the conclusion of this paper is negligible.

A limitation of the present study is that the effects of metformin on SeP expression were not investigated in human samples. The metformin concentrations used in this study (0.25-1 mM) were higher than the blood levels of metformin in patients treated with conventional doses of the drug (10 to 40 μ M). However, it has been pointed out that concentrations of metformin in liver tissue are much higher than those in the blood because the liver receives portal vein blood which may contain materially higher doses of metformin than plasma (43). An early report indicated that metformin concentrations in the liver were greater than 250 μ mol/kg in a STZ diabetic mouse model treated with 50 mg/kg metformin (44). One previous study used 0.25-1 mM metformin in rat primary hepatocytes as more physiological range of intrahepatic concentration (43). In addition, we show that administration of 300 mg/kg of metformin was effective on hepatic expression for *Sepp1* in C57BL/6J mice (Fig. 1F). Although clinical trials are necessary, we speculate here that

treatment with metformin decreases blood levels of SeP in patients with diabetes. Additionally, the contribution of SeP suppression to the anti-diabetic actions of metformin should be confirmed by additional investigations using *Sepp1*-knockout mice.

In summary, the present data provide a novel mechanism of action for metformin involving improvement of systemic insulin sensitivity via the regulation of SeP production (Fig. 6E), and suggest that AMPK/FoxO3a pathway in the liver may be a therapeutic target to the development of new-anti diabetic drugs.

REFERENCE

1. Burk, R. F., and Hill, K. E. (2005) Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. *Annu. Rev. Nutr.* **25**, 215–35
2. Carlson, B. A., Novoselov, S. V., Kumaraswamy, E., Lee, B. J., Anver, M. R., Gladyshev, V. N., and Hatfield, D. L. (2004) Specific excision of the selenocysteine tRNA^{[Ser]Sec} (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. *J. Biol. Chem.* **279**, 8011–7
3. Schomburg, L., Schweizer, U., Holtmann, B., Flohé, L., Sendtner, M., and Köhrle, J. (2003) Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. *Biochem. J.* **370**, 397–402
4. Hill, K. E., Zhou, J., McMahan, W. J., Motley, A. K., Atkins, J. F., Gesteland, R. F., and Burk, R. F. (2003) Deletion of selenoprotein P alters distribution of selenium in the mouse. *J. Biol. Chem.* **278**, 13640–6
5. Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., Ando, H., Takeshita, Y., Ota, T., Sakurai, M., Yamashita, T., Mizukoshi, E., Yamashita, T., Honda, M., Miyamoto, K., Kubota, T., Kubota, N., Kadowaki, T., Kim, H.-J., Lee, I., Minokoshi, Y., Saito, Y., Takahashi, K., Yamada, Y., Takakura, N., and Kaneko, S. (2010) A liver-derived secretory protein, selenoprotein P, causes insulin resistance. *Cell Metab.* **12**, 483–95
6. Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhashi, H., Schinkel, A. H., and Sugiyama, Y. (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. *J. Pharmacol. Exp. Ther.* **302**, 510–5
7. Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., Brett, C. M., and Giacomini, K. M. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. *J. Clin. Invest.* **117**, 1422–31
8. Boyle, J. G., Salt, I. P., and McKay, G. A. (2010) Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. *Diabet. Med.* **27**, 1097–106

9. Malin, S. K., Gerber, R., Chipkin, S. R., and Braun, B. (2012) Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. *Diabetes Care* **35**, 131–6
10. Singh, S., Akhtar, N., and Ahmad, J. (2012) Plasma adiponectin levels in women with polycystic ovary syndrome: impact of Metformin treatment in a case-control study. *Diabetes Metab. Syndr.* **6**, 207–11
11. Shargorodsky, M., Omelchenko, E., Matas, Z., Boaz, M., and Gavish, D. (2012) Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatitis: effects beyond glucose lowering? *Cardiovasc. Diabetol.* **11**, 61
12. Medema, R. H., Kops, G. J., Bos, J. L., and Burgering, B. M. (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* **404**, 782–7
13. Luo, X., Puig, O., Hyun, J., Bohmann, D., and Jasper, H. (2007) Foxo and Fos regulate the decision between cell death and survival in response to UV irradiation. *EMBO J.* **26**, 380–90
14. Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffey, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., and Burgering, B. M. T. (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* **419**, 316–21
15. Olmos, Y., Valle, I., Borniquel, S., Tierrez, A., Soria, E., Lamas, S., and Monsalve, M. (2009) Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. *J. Biol. Chem.* **284**, 14476–84
16. Greer, E. L., Oskoui, P. R., Banko, M. R., Maniar, J. M., Gygi, M. P., Gygi, S. P., and Brunet, A. (2007) The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. *J. Biol. Chem.* **282**, 30107–19
17. Sanchez, A. M. J., Csibi, A., Raibon, A., Cornille, K., Gay, S., Bernardi, H., and Candau, R. (2012) AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1. *J. Cell. Biochem.* **113**, 695–710
18. Li, X.-N., Song, J., Zhang, L., LeMaire, S. A., Hou, X., Zhang, C., Coselli, J. S., Chen, L., Wang, X. L., Zhang, Y., and Shen, Y. H. (2009) Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. *Diabetes* **58**, 2246–57

19. Lützner, N., Kalbacher, H., Krones-Herzig, A., and Rösl, F. (2012) FOXO3 is a glucocorticoid receptor target and regulates LKB1 and its own expression based on cellular AMP levels via a positive autoregulatory loop. *PLoS One* **7**, e42166
20. Honda, M., Takehana, K., Sakai, A., Tagata, Y., Shirasaki, T., Nishitani, S., Muramatsu, T., Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shimakami, T., Yi, M., Lemon, S. M., Suzuki, T., Wakita, T., and Kaneko, S. (2011) Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. *Gastroenterology* **141**, 128–40, 140.e1–2
21. Dreher, I., Jakobs, T. C., and Köhrle, J. (1997) Cloning and characterization of the human selenoprotein P promoter. Response of selenoprotein P expression to cytokines in liver cells. *J. Biol. Chem.* **272**, 29364–71
22. Takebe, G., Yarimizu, J., Saito, Y., Hayashi, T., Nakamura, H., Yodoi, J., Nagasawa, S., and Takahashi, K. (2002) A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. *J. Biol. Chem.* **277**, 41254–8
23. Nakamura, S., Takamura, T., Matsuzawa-Nagata, N., Takayama, H., Misu, H., Noda, H., Nabemoto, S., Kurita, S., Ota, T., Ando, H., Miyamoto, K.-I., and Kaneko, S. (2009) Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. *J. Biol. Chem.* **284**, 14809–18
24. Flicek, P., Amode, M. R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fairley, S., Fitzgerald, S., Gil, L., Gordon, L., Hendrix, M., Hourlier, T., Johnson, N., Kähäri, A. K., Keefe, D., Keenan, S., Kinsella, R., Komorowska, M., Koscielny, G., Kulesha, E., Larsson, P., Longden, I., McLaren, W., Muffato, M., Overduin, B., Pignatelli, M., Pritchard, B., Riat, H. S., Ritchie, G. R. S., Ruffier, M., Schuster, M., Sobral, D., Tang, Y. A., Taylor, K., Trevanion, S., Vandrovcova, J., White, S., Wilson, M., Wilder, S. P., Aken, B. L., Birney, E., Cunningham, F., Dunham, I., Durbin, R., Fernández-Suarez, X. M., Harrow, J., Herrero, J., Hubbard, T. J. P., Parker, A., Proctor, G., Spudich, G., Vogel, J., Yates, A., Zadissa, A., and Searle, S. M. J. (2012) Ensembl 2012. *Nucleic Acids Res.* **40**, D84–90
25. Paten, B., Herrero, J., Beal, K., Fitzgerald, S., and Birney, E. (2008) Enredo and Pecan: genome-wide mammalian consistency-based multiple alignment with paralogs. *Genome Res.* **18**, 1814–28
26. Wingender, E. (2008) The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. *Brief. Bioinform.* **9**, 326–32

27. Kel, A. E., Gössling, E., Reuter, I., Cheremushkin, E., Kel-Margoulis, O. V., and Wingender, E. (2003) MATCH: A tool for searching transcription factor binding sites in DNA sequences. *Nucleic Acids Res.* **31**, 3576–9
28. Speckmann, B., Sies, H., and Steinbrenner, H. (2009) Attenuation of hepatic expression and secretion of selenoprotein P by metformin. *Biochem. Biophys. Res. Commun.* **387**, 158–63
29. A. Łukaszewicz-Hussain, and J. Moniuszko-Jakoniuk (2004) Liver Catalase, Glutathione Peroxidase and Reductase Activity, Reduced Glutathione and Hydrogen Peroxide Levels in Acute Intoxication with Chlorfenvinphos, an Organophosphate Insecticide. *Polish J. Environ. Stud.* **13**, 303–309
30. Magwere, T., Naik, Y. S., and Hasler, J. A. (1997) Effects of chloroquine treatment on antioxidant enzymes in rat liver and kidney. *Free Radic. Biol. Med.* **22**, 321–7
31. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. *J. Clin. Invest.* **108**, 1167–74
32. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* **96**, 857–68
33. Eckers, A., Sauerbier, E., Anwar-Mohamed, A., Hamann, I., Esser, C., Schroeder, P., El-Kadi, A. O. S., and Klotz, L.-O. (2011) Detection of a functional xenobiotic response element in a widely employed FoxO-responsive reporter construct. *Arch. Biochem. Biophys.* **516**, 138–45
34. Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., and Auwerx, J. (2009) AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature* **458**, 1056–60
35. Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., and Spiegelman, B. M. (2003) Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1 α interaction. *Nature* **423**, 550–5
36. Hosaka, T., Biggs, W. H., Tieu, D., Boyer, A. D., Varki, N. M., Cavenee, W. K., and Arden, K. C. (2004) Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 2975–80

37. Haeusler, R. a, Kaestner, K. H., and Accili, D. (2010) FoxOs function synergistically to promote glucose production. *J. Biol. Chem.* **285**, 35245–8
38. Speckmann, B., Walter, P. L., Alili, L., Reinehr, R., Sies, H., Klotz, L.-O., and Steinbrenner, H. (2008) Selenoprotein P expression is controlled through interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. *Hepatology* **48**, 1998–2006
39. Walter, P. L., Steinbrenner, H., Barthel, A., and Klotz, L.-O. (2008) Stimulation of selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription factor. *Biochem. Biophys. Res. Commun.* **365**, 316–21
40. Van Der Heide, L. P., Hoekman, M. F. M., and Smidt, M. P. (2004) The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. *Biochem. J.* **380**, 297–309
41. Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., Marette, A., Kozma, S. C., and Thomas, G. (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. *Cell Metab.* **11**, 390–401
42. Guigas, B., Bertrand, L., Taleux, N., Foretz, M., Wiernsperger, N., Vertommen, D., Andreelli, F., Viollet, B., and Hue, L. (2006) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. *Diabetes* **55**, 865–74
43. Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., and Viollet, B. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J. Clin. Invest.* **120**, 2355–69
44. Wilcock, C., and Bailey, C. J. (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. *Xenobiotica* **24**, 49–57

Acknowledgments- The authors thank Dr. Atsushi Hirao (Kanazawa University) for providing a vector for FHRE-Luc and Ms. Maki Wakabayashi (Kanazawa University) for technical assistance. The authors thank Fabienne Foufelle of Université Pierre et Marie Curie for providing adenovirus vector encoding DN-AMPK. The authors thank In-kyu Lee of Kyungpook National University for providing adenovirus vector encoding CA-AMPK. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to H.M., T.T. and S.K.) and research grants from Dainippon Sumitomo Pharma (to S.K.) and Takeda Science Foundation (to H.M.).

Figure Legends

FIGURE 1. Metformin suppressed *Sepp1* gene expression in H4IIEC3 hepatocytes and livers of C57BL/6J mice. *A* and *B*: Metformin suppressed *Sepp1* mRNA expression in a concentration- and time-dependent manner. H4IIEC3 cells were treated with the indicated concentrations of metformin for the indicated times. Expression values were normalized to *Actb* mRNA. Data represent means \pm SD (n = 4). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ versus vehicle-treated cells or 0 h. *C* and *D*: *SEPP1* promoter activity was suppressed in a concentration- and time-dependent manner. H4IIEC3 cells were transfected with the *SEPP1* promoter reporter vector and control reporter vector. 24 h later, the cells were treated with the indicated concentrations of metformin for the indicated times. Values were normalized to the activity of the control luciferase vector. Data represent means \pm SD (n = 4). **, $P < 0.01$; ***, $P < 0.001$ versus vehicle-treated cells or 0 h. *E* and *F*: Metformin suppressed *Sepp1* mRNA expression in livers of C57BL/6J mice. Following the fasting for 4 hours, 12 weeks old female C57BL/6J mice were administrated 300 mg/kg of metformin. 4 h after metformin administration, mice were sacrificed and liver mRNA expression was examined. Expression values were normalized to *Actb* mRNA. Data represent means \pm SD (n = 7). *, $P < 0.05$ versus PBS-injected mice.

FIGURE 2. Metformin suppressed *SEPP1* promoter activity via AMPK pathway in H4IIEC3 hepatocytes. *A*: Metformin-induced AMPK phosphorylation in the absence or presence of compound C. H4IIEC3 cells were treated with the indicated concentrations of metformin and compound C for 24 h. AMPK phosphorylation was examined by Western blotting. *B*: Compound C treatment recovered metformin-induced suppression of the *SEPP1* promoter. H4IIEC3 cells were transfected with the *SEPP1* promoter reporter vector and control reporter vector at 24 h and then treated with the indicated concentrations of metformin and compound C for 48 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). ***, $P < 0.001$. *C*: AICAR suppressed *SEPP1* promoter activity. H4IIEC3 cells were transfected with the *SEPP1* promoter reporter vector and control reporter vector at 24 h and then treated with 0.4 mM AICAR for 24 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). ***, $P < 0.001$. *D* and *E*: Influence of adenoviruses carrying CA- or DN-AMPK. H4IIEC3 cells were infected with adenoviruses encoding CA, DN or LacZ. Expression values were normalized to *Actb* mRNA. Data represent means \pm SD (n = 4). **, $P < 0.01$; ***, $P < 0.001$.

FIGURE 3. *SEPP1* promoter activity of deletion mutants. *A* and *B*: Structure and luciferase activity of promoter-deletion mutants. The sequences deleted within the constructs are shown as thin lines. The remaining parts of the *SEPP1* promoter were fused to a luciferase reporter gene. H4IIEC3 cells were transfected with each reporter vector and control reporter vector at 24 h and then treated with the indicated concentrations of

metformin for 48 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). ***, $P < 0.001$ versus vehicle-treated cells.

FIGURE 4. Activation of the AMPK suppressed FoxO activity. *A:* Putative FoxO3a binding sites of Mut-D Δ 2 sequence. Detection of the conserved transcription factor binding sites (TFBSs) was performed using multiple genome alignments and the highlighted putative transcriptional factor binding sites. *B:* FoxO activity in the absence or presence of metformin and compound C. H4IIEC3 cells were transfected with the FHRE-Luc vector and control reporter vector at 24 h and then treated with the indicated concentrations of metformin and compound C for 48 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). **, $P < 0.01$; ***, $P < 0.001$. *C:* FoxO activity in the absence or presence of AICAR. H4IIEC3 cells were transfected with the FHRE-Luc vector and control reporter vector at 24 h and then treated with the indicated concentrations of AICAR for 24 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). *, $P < 0.05$ versus vehicle-treated cells. *D:* Deficiency of putative FoxO binding site cancelled metformin-induced suppression of *SEPP1* promoter activity. H4IIEC3 cells were transfected with each reporter vector and control reporter vector at 24 h and then treated with the indicated concentrations of metformin for 24 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). ***, $P < 0.001$ versus vehicle-treated cells. *E:* Chromatin immunoprecipitation assay of HepG2 cells treated with metformin. HepG2 Cells were treated with metformin for 6 h. Chromatin samples precipitated with anti-FoxO3a, anti-FoxO1, or normal IgG were amplified using primers for the -200 to -100 bp region of the human *SEPP1* promoter.

FIGURE 5. Metformin suppressed SeP expression via FoxO3a. *A:* Efficiency of *Foxo3a* siRNA and *Foxo1* siRNA. H4IIEC3 cells were transfected with *Foxo3a* siRNAs or *Foxo1* siRNAs or a negative control (NC) siRNA at 48 h. Knockdown efficiency was assessed by real-time PCR. Expression values were normalized to *Actb* mRNA. Data represent means \pm SD (n = 4). **, $P < 0.01$; ***, $P < 0.001$ versus NC siRNA-treated cells. *B:* Luciferase activity of Mut-D Δ 2 treated with *Foxo3a* or *Foxo1* siRNA and metformin. H4IIEC3 cells were transfected with *Foxo3a* siRNAs or *Foxo1* siRNAs or NC siRNA at 24 h and then transfected with Mut-D Δ 2 vector and control reporter vector. 24 h after transfection, cells were treated with the indicated concentrations of metformin for 24 h. Signals were normalized to the control reporter vector. Data represent means \pm SD (n = 4). ***, $P < 0.001$ versus vehicle-treated cells. *C:* Protein levels in the presence of the FoxO3a overexpression vector. H4IIEC3 cells were transfected with the pCMV-FoxO3a vector or pCMV empty vector at 24 h. FoxO3a protein levels were then assessed by Western blotting. *D:* *SEPP1* promoter activity transfected with the FoxO3a-overexpression vector. H4IIEC3 cells were transfected with the FoxO3a overexpression vector, *SEPP1* promoter reporter vector, and control reporter vector at 24 h and then treated with the indicated concentrations of metformin for 48 h. Data represent means \pm SD (n = 3-4). ***, $P < 0.001$ versus control, ††, $P < 0.01$; †††, $P < 0.001$ versus vehicle-treated cells. *E:* % inhibition of *SEPP1* promoter activity by metformin.

Suppression ratios of *SEPP1* promoter activity were calculated based on the data in Fig. 5E. Data represent means \pm SD (n = 3-4). **, $P < 0.01$; ***, $P < 0.001$ versus control.

FIGURE 6. Metformin treatment did not suppress FoxO3a expression but did suppress its activity. *A*: *FoxO3a* mRNA expression in H4IIEC3 hepatocytes treated with metformin for 6 h. Expression values were normalized to *Actb* mRNA. Data represent means \pm SD (n = 5-6). *B and C*: Modification of FoxOs proteins by metformin treatment. Proteins were extracted after 6 h of metformin treatment. Immunoblotting were performed using anti-FoxO3a antibody (B) or anti-FoxO1 antibody (C). Data represent means \pm SD (n = 3). **, $P < 0.01$. *D*: Intracellular localization of FoxO3a and FoxO1 in H4IIEC3 hepatocytes upon treatment with metformin. Proteins were extracted after 6 h of metformin treatment. *E*: Scheme of SeP suppression by metformin in the liver. FoxO3a positively regulates *SEPP1* promoter activity. Metformin suppresses FoxO3a activity via AMPK activation, resulting in suppression of SeP expression. Thus the hypoglycemic effects of metformin may be mediated at least in part by SeP suppression in the liver.

TABLE 1

Primers used in cloning

<i>SEPP1</i> -Promoter-Luc	Forward	hSeP-promoter-F-BglIII	ACTAGATCTACAAACCTTTCAGACACTGAGTTG
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-A	Forward	hSeP-Promoter-Del-F1-BglIII	ACTAGATCTGGGCTGCCTGTCTTTGATTTACAT
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mu-B	Forward	hSeP-Promoter-Del-F2-BglIII	ACTAGATCTTTGTAGTTCCTGCACCTTGTACAAC
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-C	Forward	hSeP-Promoter-Del-F3-BglIII	ACTAGATCTGCATAGGTCTTCCAGGAAGTACGAC
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-D	Forward	hSeP-Promoter-Del-F4-BglIII	ACTAGATCTCAAATGTTTTTCCCTGTTATAGTTT
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-E	Forward	hSeP-promoter-F-BglIII	ACTAGATCTACAAACCTTTCAGACACTGAGTTG
	Reverse	hSeP-promoter-Del-R1-NcoI	ACTCCATGGCTGAGCCAGCGAATTATGCTGCTGC
Mut-DΔ1	Forward	hSeP-Promoter-Del-F14-BglIII	ACTAGATCTGATTCTAGGGTGACTGAAAAGGATA
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-DΔ2	Forward	hSeP-Promoter-Del-F15-BglIII	ACTAGATCTATAACAATCAGCTCAGGGGTTTGCT
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-DΔ3	Forward	hSeP-Promoter-Del-F16-BglIII	ACTAGATCTATAAATATCAGAGTGTGCTGCTGTG
	Reverse	hSeP-promoter-R-NcoI	ACTCCATGGACAACCACTTCCAACGGGCCTGCTT
Mut-DΔ2-ΔFoxo #A	Forward	del86-95	GACTATACCTGAGGGGTGAGGGACTATAAATATCAGAGTG
	Reverse	del86-95-antisense	CACTCTGATATTTATAGTCCCTCACCCCTCAGGTATAGTC
Mut-DΔ2-ΔFoxo #B	Forward	hSeP-del-Foxo #3-F	GAGGTAAACAACAGGACTAAGAGTGTGCTGCTGTGG
	Reverse	hSeP-del-Foxo #3-R	CCACAGCAGCACACTCTTAGTCCTGTTGTTTACCTC

Figure 1




Figure 2





Figure 3

A



B




Figure 4






Figure 5


A




B



C



D



E




Figure 6

